INDV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -1.46%, SMA50 -2.74%, SMA200 33.96%). The stock’s 14-day RSI is 46.73 (neutral), while the ATR of 1.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.29% below its high and over 319.28% above its low. Average 10-day trading volume of 1.73 million shares is in line with the 3-month average of 1.90 million, indicating normal recent market interest.

Indivior Pharmaceuticals Inc has 124.77 million shares outstanding. The public float is 89.80 million shares, elevated short interest at 5.76% of float. This equals 7.12 million shares. The short ratio is 2.08 days. Institutional investors hold 92.39% of the float. Insiders own 1.39%. Preblick Ryan holds 284.75 thousand shares, Heidbreder Christian has 227.92 thousand shares and NINIVAGGI DANIEL A has 16.92 thousand shares. Over the past six months, insider transactions show net buying. They sold 54.59 thousand shares across 2 transactions.

Indivior Pharmaceuticals Inc generated EPS of $1.00 over the past year. Five-year average earnings growth is -56.08%. Wall Street analysts project EPS growth of 26.21% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $48.00 to $20.00. The high target offers 25.26% upside. The low target suggests -47.81% downside. The mean target is $34.25. This offers -10.62% upside. Indivior Pharmaceuticals Inc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 30, 2026, missed forecasts by 10.94%. The prior quarter beat by 26.15%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in February 20, 2025.

Indivior Pharmaceuticals Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.19. This means the shares are trading below this model’s fair value.

Indivior Pharmaceuticals Inc (NASDAQ:INDV) closed at $38.32 USD, gaining $0.02 (0.05%) from the previous close of $38.30. The stock is currently mid-range between its 52-week high and low $13.47 and $41.00. With a market capitalization of about $4.78 billion, Indivior Pharmaceuticals Inc is classified as a mid-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 1.97 million shares, volume is running light vs its 52-week average. Headquartered in North Chesterfield, VA, Indivior Pharmaceuticals Inc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Joseph J. Ciaffoni, the company employs approximately 1,030 people and listed since December 29, 2014. Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence.

Indivior Pharmaceuticals Inc trades at a P/E ratio of 19.08, slightly below the S&P 500 average, with a price-to-sales ratio of 3.71 and a price-to-book ratio of -33.38 indicating negative book value, which may reflect financial stress. The P/FCF stands at -25.92, also below market averages.

Our AI price prediction model suggests that Indivior Pharmaceuticals Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.86%, with price expected at $38.65 by July 06, 2026, within a range of $37.13 to $40.31 3-Month Outlook: Projected rise of 20.69%, reaching $46.25 by September 18, 2026, with a range of $45.86 to $46.58. 1-Year Outlook: Projected gain of 13.1%, with price at $43.34 by June 22, 2027, within a range of $40.97 to $46.64.

Indivior Pharmaceuticals Inc (NASDAQ:INDV) shares are flat -8.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Indivior Pharmaceuticals Inc trading at a premium to the broader market with a P/E of 19.08. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $27.57, suggesting -28.05% downside. Our AI forecast model points to short-term strength (0.86% over two weeks), a medium-term rise (20.69% over three months), and a longer-term gain (13.1% over one year), with expected trading ranges indicating moderate volatility.